Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hRPC subretinal transplantation in retinitis pigmentosa
2019-004547-77Phase 2Unknown
- Sponsor
- ReNeuron
- Start
- Feb 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of famzeretcel in retinitis pigmentosa (RP) (3 arms), sponsored by ReNeuron. Primary endpoint: Safety over six months after treatment. Status: unknown.
02
Drugs
famzeretcel
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on 2019-004547-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004547-77.